Savara, Inc. (SVRA)

Over the past six months, Savara's stock has shown positive momentum, with a 1-month share price return of 9.68% and a 1-year total shareholder return of 122.31% as of April 8, 2026. The stock price was $5.56 per share on April 2, 2026, a 102.18% increase over the previous year. Key events include the MHRA accepting the MOLBREEVI* MAA on April 7, 2026, the EMA validating the MAA on March 30, 2026, the release of the Fourth Quarter and Year End 2025 Financial Results on March 13, 2026, and the FDA filing the MOLBREEVI* BLA and granting it Priority Review with a PDUFA date of August 22, 2026, on March 4, 2026.

Specific demand seasonality for Savara, Inc.'s products and services is not explicitly detailed. As a clinical-stage biopharmaceutical company focused on rare respiratory diseases, direct consumer demand seasonality is less likely to be a primary factor.

Savara, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases, operating within the biotechnology and pharmaceutical industries. Their primary product candidate is MOLBREEVI* (molgramostim), in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Savara has also in-licensed Brensocatib, being evaluated for non-cystic fibrosis bronchiectasis (NCFBE) and nontuberculous mycobacterial (NTM) lung infections. The company aims to expand its pipeline through indication expansion, partnerships, and acquisitions.

Savara, Inc. is headquartered in Langhorne, Pennsylvania, United States, and conducts research and development in North America and Europe. MOLBREEVI* has marketing authorization applications accepted by the U.K. MHRA and validated by the EMA. Savara has also launched an aPAP ClearPath antibody test in Europe.

Savara's brand reputation has seen both positive and negative influences in the past year. Positive clinical results for molgramostim have improved the company's outlook, with analysts giving a consensus rating of "Moderate Buy" and projections for increased worldwide peak sales. However, the company's stock price fell by 31.69% on May 27, 2025, after receiving a "Refusal to File" letter from the FDA for the MOLBREEVI BLA due to CMC data requests, and a class action complaint was filed on September 8, 2025, alleging insufficient disclosure regarding MOLBREEVI's CMC.

Savara, Inc.'s ownership is predominantly institutional, with 159 institutional owners holding 189,841,500 shares, representing approximately 79.95% to 89.46% of the stock. Major institutional shareholders include NEA Management Company, LLC, Bain Capital Life Sciences Investors, LLC, and VR Adviser, LLC. Insiders hold approximately 2.97% to 5.33% of the stock. Public companies and individual investors own about 7.57% to 9.52% of the shares. Edward T. Mathers is the largest individual shareholder, holding 24.47 million shares, representing 11.96% of the company.